Imfinzi gastric cancer treatment has received European Commission approval for adults with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. AstraZeneca’s Imfinzi (durvalumab), a PD-L1 inhibitor, combined with FLOT chemotherapy...

Europe life sciences competitiveness is under pressure, as detailed in the EFPIA report "Asses...

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucagon-like peptide-1 (GLP-1) receptor agonists for ty...

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report detailing 104 positive recommendations for new hu...

Cancer productivity losses from premature mortality and morbidity due to leading cancers across 28 European countries in 2022 totaled €39.8 billion, as estimated via the human capital approach in this study....

Voxzogo reimbursement Netherlands hangs in limbo after Biomarin's decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas.